4 Under-the-Radar Stocks With 319% to 645% Upside in 2022, According to Wall StreetThe Motley Fool • 01/29/22
Pomerantz Law Firm Announces the Filing of a Class Action against Intercept Pharmaceuticals, Inc. and Certain Officers - ICPTPRNewsWire • 01/06/22
Intercept Pharmaceuticals Provides Update on Phase 3 REVERSE Trial in Compensated Cirrhosis Due to NASHGlobeNewsWire • 12/20/21
Is the Options Market Predicting a Spike in Intercept (ICPT) Stock?Zacks Investment Research • 12/10/21
Intercept Announces Withdrawal of EMA Marketing Authorization Application for Obeticholic Acid for Advanced Liver Fibrosis Due to NASHGlobeNewsWire • 12/09/21
Intercept (ICPT) Down 10.7% Since Last Earnings Report: Can It Rebound?Zacks Investment Research • 12/03/21
Intercept Posts Long-Term Data For Obeticholic Acid In Chronic Liver Disease PatientsBenzinga • 11/15/21
Intercept Announces New Long-Term Data Demonstrating Potential of Obeticholic Acid to Improve Transplant-Free Survival in Patients with PBCGlobeNewsWire • 11/15/21
Intercept Pharmaceuticals, Inc. (ICPT) CEO Jerry Durso on Q3 2021 Results - Earnings Call TranscriptSeeking Alpha • 11/03/21
Intercept Pharmaceuticals Reports Third Quarter 2021 Financial Results and Provides Business UpdateGlobeNewsWire • 11/03/21
Intercept Announces Late-Breaking Oral Presentation and Poster Presentations at The Liver MeetingGlobeNewsWire • 11/02/21
SHAREHOLDER ALERT: Kaskela Law LLC Announces Investigation of Intercept Pharmaceuticals, Inc. (ICPT) and Encourages Long-Term ICPT Stockholders to Contact the FirmNewsfile Corp • 10/23/21
Wall Street Analysts Think Intercept (ICPT) Could Surge 95%: Read This Before Placing a BetZacks Investment Research • 10/14/21